secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2026-06-01T12:10:58+00:00
Accession:  0001104659-26-068604
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027
--------------------------------------------------------------------------------

- ORR of 55% (11/20) in gynecologic cancers at 4.8-8.0 mg/kg with ≥12 wks follow-up; 52.9% in ovarian, 66.7% in USC.
- TEAEs leading to dose discontinuation in 3 patients (Gr2 ILD, Gr3 fungal pneumonia, Gr4 thrombocytopenia); no primary prophylaxis for hematologic toxicities used.
- Patients heavily pretreated: median 5 prior systemic regimens (range 1-12); 78% ovarian cancer.
- Cash, cash equivalents and marketable securities expected to fund operations into Q1 2027.
- Virtual KOL event scheduled for June 2, 2026 at 8 AM ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000110465926068604/0001104659-26-068604-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000110465926068604/nxtc-20260601x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-068604

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer